Welcome to our dedicated page for Positron news (Ticker: POSC), a resource for investors and traders seeking the latest updates and insights on Positron stock.
Positron Corporation develops and commercializes PET and PET-CT molecular imaging systems and related clinical services for nuclear medicine providers in North America. The company specializes in cardiac Positron Emission Tomography applications, including PET-CT scanners and practice support for cardiovascular diagnostic providers.
Company news commonly covers scanner sales and multi-unit orders, long-term service agreements, the NeuSight PET-CT 64-slice system, industry partnerships, product development, regulatory activities, capital raises, and its transition to SEC reporting status. Updates also describe how Positron combines imaging hardware, software, clinical support, technical support, and training services for nuclear cardiology and broader molecular imaging practices.
Positron (OTC: POSC) has announced the sale of its Attrius® PET System to a cardiovascular practice in Michigan. The installation is scheduled for Q4 2024. The Attrius PET scanner excels in nuclear cardiology, offering high-resolution images and precise blood flow analysis. The new customer will benefit from Positron's Lease to Own Program, which requires zero upfront capital expenditure and includes the complete Attrius PET System and comprehensive clinical and technical services for a monthly fee. Positron's President, Adel Abdullah, emphasized the system's ability to enhance cardiac diagnostics and its cost-effective operational model for nuclear imaging practices.
Positron (OTC: POSC), a leading molecular imaging medical device company, has joined the Cardiac PET Industry Coalition (CPIC). The coalition includes founding members such as Bracco Diagnostics, CDL Nuclear Technologies, and Siemens Healthcare, united to promote federal policies enhancing healthcare outcomes for cardiovascular disease patients. CPIC aims to improve access to cardiac PET diagnostics across the U.S., advocate for fair reimbursement policies, and educate healthcare providers and policymakers on the benefits of cardiac PET. Positron President Adel Abdullah emphasized the company's commitment to the coalition's goals and its role in advancing PET technology.
Positron (OTC: POSC) has secured exclusive North American rights to sell and distribute the NeuSight PET-CT 64 slice scanner through an agreement with Shenyang Intelligent Nuclear Medical Technology Co., a subsidiary of Neusoft Medical Systems. This award-winning scanner has FDA clearance for the US market and will be introduced in July 2024 for nuclear cardiac imaging. NeuSight PET-CT 64 offers advanced imaging for heart, tumor, and brain studies, combining anatomical and functional imaging with improved speed and accuracy. Positron aims to meet the increasing demand in the US, Canada, and Mexico, leveraging the system’s international success, with around 500 units sold globally.
Positron (OTC: POSC) has entered an agreement to acquire the FDA 510(k) clearance for the NeuSight PET-CT from Neusoft Medical Systems' subsidiary. This acquisition enables Positron to immediately market and sell the NeuSight PET-CT 64 slice imaging system and facilitates future FDA clearances for their Affinity PET-CT 4D 64 slice system. Adel Abdullah, President of Positron, emphasized that this milestone will significantly enhance their product line, which is vital for both oncology and nuclear cardiology. Positron aims to offer advanced PET-CT technology to healthcare practices, supported by Neusoft's extensive R&D expertise.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Positron Corporation (OTC: POSC) has entered a Clinical Study/Research Agreement with Ochsner Clinic Foundation for its new Affinity™ PET-CT 4D device. This agreement facilitates the collection of safety and efficacy data, crucial for obtaining an Investigational Device Exemption (IDE) from the FDA. The independent Institutional Review Board has approved all study procedures, allowing preparations for patient scans to begin post-IDE approval. The company aims for completion of the clinical study and FDA certification within 60 days, marking a significant step toward commercialization.